Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUL45H)

Drug Name
Naltrexone Drug Info
Synonyms
Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
Cross-matching ID
PubChem CID
5360515
ChEBI ID
CHEMBL19019
CAS Number
CAS 16590-41-3
TTD Drug ID
D0PG8O
VARIDT Drug ID
DR00968
INTEDE Drug ID
DR1128
ACDINA Drug ID
D00455

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Base excision repair 2.02 0.00e+0 29/33 (87.88%) PCNA;APEX1;POLE3;...
Ribosome 2.02 0.00e+0 113/158 (71.52%) RPS4Y1;RPL10;RPL14;...
Renin-angiotensin system 1.95 7.26e-3 20/23 (86.96%) AGTR1;ANPEP;MME;...
Tyrosine metabolism 1.89 2.18e-2 30/36 (83.33%) MAOA;COMT;ADH1B;...
Drug metabolism 1.78 4.36e-2 78/151 (51.66%) MAOA;NME4;ADH1B;...
Primary immunodeficiency -1.71 4.52e-2 33/38 (86.84%) CD3D;IGLL1;TAP1;...
Ferroptosis -1.72 4.29e-2 36/41 (87.8%) SLC39A14;FTH1;MAP1LC3B;...
Circadian rhythm -1.73 4.35e-2 26/31 (83.87%) PER3;PRKAB1;CSNK1E;...
Pertussis -1.82 1.75e-2 64/76 (84.21%) IRAK1;C1S;IL1B;...
IL-17 signaling pathway -1.82 2.04e-2 84/94 (89.36%) CCL7;MUC5B;IL1B;...
Epithelial cell signaling in Helicobacter pylori infect... -1.85 1.51e-2 62/70 (88.57%) RELA;F11R;CHUK;...
Terpenoid backbone biosynthesis -1.87 1.18e-2 18/22 (81.82%) ACAT2;DHDDS;MVD;...
Steroid biosynthesis -1.93 1.25e-2 19/20 (95%) LSS;FDFT1;DHCR24;...
TNF signaling pathway -2.02 9.41e-3 103/112 (91.96%) CREB1;IL6;CREB3L1;...
Rheumatoid arthritis -2.07 9.41e-3 78/93 (83.87%) VEGFA;LTB;HLA-DRB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H